Dimethyl morpholinophosphoramidate

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

SMALL SPILLS AND LEAKAGE: If you should spill this chemical, use absorbent paper to pick up all liquid spill material. Seal the absorbent paper, as well as any of your clothing which may be contaminated, in a vapor-tight plastic bag for eventual disposal. Wash any surfaces you may have contaminated with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

The following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the "Standard Toxicology & Carcinogenesis Studies", "Developmental Studies", and "Genetic Toxicity Studies" performed with this chemical. Clicking on the "Testing Status" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical. [http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=597-25-1]

Dimethyl morpholinophosphoramidate

TR-298: Toxicology and Carcinogenesis Studies of Dimethyl Morpholinophosphoramidate (CASRN 597-25-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies) (1986 )

11/02/84

Some Evidence

Some Evidence

No Evidence

100 DAYS OF DERMAL APPLICATIONS TO RABBITS WAS WITHOUT EFFECT. THE SAME TREATMENT TO BOTH MALE & FEMALE RATS DID NOT EFFECT BREEDING. HIGHEST DOSE HAVING NO EFFECT WAS 0.5 G/KG/DAY.

DMMPA SHOWED VERY LOW TOXICITY WHEN ADMIN ACUTELY TO MICE, & 28 DAYS OF APPLICATION TO SKIN OF RATS & RABBITS PRODUCED NO EVIDENCE OF DAMAGE TO SKIN.

IN MICE, RATS & RABBITS MAXIMUM NONTOXIC DOSE WAS IN NO CASE LESS THAN THE ESTIMATED LD(0) DOSE, INDICATING COMPD WAS REMARKABLY NONTOXIC & SAFE FOR ACUTE EXPOSURES OF SMALL AMT TO MAN.

Dimethyl morpholinophosphoramidate was evaluated for mutagenicity in the Salmonella/microsome preincubation assay using a standard protocol approved by the National Toxicology Program. Doses of 0, 100, 333, 1000, 3333, and 10,000 ug/plate were tested in four Salmonella typhimurium strains (TA98, TA100, TA1535, and TA1537) in the presence and absence of Aroclor-induced rat or hamster liver S9. These tests were negative and the highest ineffective dose level tested in any Salmonella tester strain was 10,000 ug/plate.

... Under the conditions of these 2 yr gavage studies, there was some evidence of carcinogenicity for male and female F344/N rats given dimethyl morpholinophosphoramidate, as indicated by incr incidences of mononuclear cell leukemia. There was no evidence of carcinogenicity for male and female B6C3F1 mice given dimethyl morpholinophosphoramidate at doses of 150 (male), 300 or 600 (female) mg/kg for 2 yr.

... In the 2 yr toxicology and carcinogenesis studies, groups of 50 male and 50 female F344/N rats were given dimethylmorpholinophosphoramidate in corn oil by gavage at doses of 0, 150, 300, or 600 mg/kg body weight, 5 days per week for 103 weeks. Groups of 50 male B6C3F1 mice were given dimethylmorpholinophosphoramidate at 0, 150, 300 mg/kg body weight, and groups of 50 female B6C3F1 mice were given dimethylmorpholinophosphoramide at 0, 300, 600 mg/kg body weight on the same schedule. ... Under the conditions of these 2 yr gavage studies, there was some evidence of carcinogenicity for male and female F344/N rats given dimethyl morpholinophosphoramidate, as indicated by incr incidences of mononuclear cell leukemia. There was no evidence of carcinogenicity for male and female B6C3F1 mice given dimethyl morpholinophosphoramidate at doses of 150 (male), 300 or 600 (female) mg/kg for 2 yr.